Bhavini Mishra, Sanket Koul

Stories by Bhavini Mishra, Sanket Koul

Indian Student Numbers Surge at UCL

Indian Student Numbers Surge at UCL

Rediff.com   21 hours ago

University College London has recorded a 19 per cent and 26 per cent rise in undergraduate and postgraduate students from India for the 2026 term, indicating a preference for the UK over the US at a time when Indian students are facing visa uncertainties in US-based institutions.

Pan masala cess to boost public health, security

Pan masala cess to boost public health, security

Rediff.com   3 days ago

Experts said that earmarking of funds for public health at par with national security indicates a key policy shift.

IIT Students Get 90 Lakh To 3 Cr Offers!

IIT Students Get 90 Lakh To 3 Cr Offers!

Rediff.com   7 days ago

Several IITs have been pushing for a diversification of job profiles as roles move beyond just tech companies and start-ups, particularly with the advent of AI.

PMJAY for 70+ covered 700K treatments in one year

PMJAY for 70+ covered 700K treatments in one year

Rediff.com   2 Dec 2025

The government aims to cover around 60 million people in the age category, irrespective of income, with an assured 5 lakh annually to be shared within the family.

Fine must be limited to jurisdiction where product is made: Apple to HC

Fine must be limited to jurisdiction where product is made: Apple to HC

Rediff.com   2 Dec 2025

The Delhi high court on Monday sought responses from the Centre and the Competition Commission of India (CCI) on Apple Inc's plea challenging recent amendments to the Competition Act that allow penalties to be based on a company's global turnover.

Global turnover penalty on Apple could cost $38bn

Global turnover penalty on Apple could cost $38bn

Rediff.com   27 Nov 2025

iPhone maker tells Delhi HC the antitrust watchdog has no jurisdiction to consider its global turnover.

Affordable homes no longer attractive to investors

Affordable homes no longer attractive to investors

Rediff.com   27 Nov 2025

Affordable homes, priced under Rs 40 lakh per unit, may not be attractive anymore, not just for developers but also for investors, with the segment seeing a 26 per cent price rise over three years since 2022 versus 40 per cent returns from luxury homes priced Rs 1.5 crore and above.

50,000 Kids Await Justice

50,000 Kids Await Justice

Rediff.com   21 Nov 2025

Without urgent corrective steps, the system meant to ensure safety, dignity, and rehabilitation for children in conflict with the law will remain overburdened, under-resourced, and unable to deliver justice in time.

Open Chest Clinics: Govt Tells States, UTs

Open Chest Clinics: Govt Tells States, UTs

Rediff.com   13 Nov 2025

The clinics are expected to operate for at least two hours daily, particularly between September and March -- the period when air pollution levels are typically high.

Selling Land Is Not a Service, Rules Supreme Court

Selling Land Is Not a Service, Rules Supreme Court

Rediff.com   12 Nov 2025

The Supreme Court has said that selling land or property is not a service under the Finance Act, 1994, so such sales cannot be charged with service tax.

Deepfake Laws Are Coming: But Are They Enough?

Deepfake Laws Are Coming: But Are They Enough?

Rediff.com   5 Nov 2025

Taming the animal called AI in its many avatars will clearly remain a work in progress.

World's Top Schools Set Sights On India

World's Top Schools Set Sights On India

Rediff.com   3 Nov 2025

In the academic year 2024-2025, the IB had 258 authorised schools in India, up from 183 schools in 2019.

Centre Moves To Bar Drugmakers Over Fake Information

Centre Moves To Bar Drugmakers Over Fake Information

Rediff.com   3 Nov 2025

At present, there is no provision under Drugs Rules, 1945 to address issues of wrong information to obtain regulatory approvals.

Fresh Air Becomes Real Estate Must-Have

Fresh Air Becomes Real Estate Must-Have

Rediff.com   1 Nov 2025

Interest in green living is rising, with clean air and open spaces becoming key selling points for residential projects, particularly as Indian cities struggle with deteriorating air quality.

Realty developers see a cracker of sales in key cities this festival season

Realty developers see a cracker of sales in key cities this festival season

Rediff.com   22 Oct 2025

India's housing market has remained resilient this festival season (Dussehra-Diwali period), despite global macroeconomic challenges, tech-sector layoffs, and affordability pressures, with developers reporting 10-25 per cent year-on-year (Y-o-Y) rise in home sales across major cities.

Realty's Next Address: SPR, Sohna Power NCR's Growth

Realty's Next Address: SPR, Sohna Power NCR's Growth

Rediff.com   18 Oct 2025

Part-I of this three-part series dives into Delhi-NCR's SPR, Sohna, Dwarka Expressway, and Jewar Airport leading the charge.

Will festive season bring cheers to India's housing sector after 3 weak quarters?

Will festive season bring cheers to India's housing sector after 3 weak quarters?

Rediff.com   13 Oct 2025

After three straight quarters of decline, India's housing market is pinning hopes on the ongoing festival season to revive sales momentum. While 2025 may still end with sales volumes below 2024 levels, developers believe the seasonally strong October-December quarter could narrow the gap, aided by stable interest rates, festive incentives, and resilient demand in the premium segment.

Cough syrup deaths: No state follows pharma safety norms

Cough syrup deaths: No state follows pharma safety norms

Rediff.com   10 Oct 2025

The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.

UK Opens Up For Indian Students

UK Opens Up For Indian Students

Rediff.com   8 Oct 2025

'Initiatives such as the Young Professionals Scheme also offer young graduates the chance to live and work in the UK after gaining experience.'

Weight Loss Drug Mounjaro Registers Rs 80 Cr Sales

Weight Loss Drug Mounjaro Registers Rs 80 Cr Sales

Rediff.com   8 Oct 2025

The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.